7 August 2017 - Just Published: article on NLX-112 analgesic activity in mouse

The Neurolixis drug candidate for treatment of dyskinesia (LID) in Parkinson's disease , NLX-112, was tested in a new study of analgesic activity. It exhibited potent analgesic activity in the mouse formalin test, a model of tonic pain, possibly through activation of spinal cord serotonin 5-HT1A receptors. NLX-112 was also active, albeit less potently, in other pain tests suggesting that it may have beneficial properties on chronic pain symptoms in Parkinson's disease , in addition to its potent anti-dyskinetic activity against L-DOPA-induced dyskinesia (LID), as previously described . Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain Sałat K, Kołaczkowski M, Furgała A, Rojek A, Śniecikowska J, Varney MA, Newman-Tancredi A Neuropharmacology. 2017 Jul 24;125:181-188. doi: 10.1016/j.neuropharm.2017.07.022.

The release as fetched from its publisher. neurolixis.com ↗